Behçet's disease: Global epidemiology of an Old Silk Road disease

British Journal of Ophthalmology

Volumn 91, Issue 12, 2007, Pages 1573-1574

  Keino, Hiroshi ^a   Okada, Annabelle A ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB;

BEHCET DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; EDITORIAL; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HUMAN; INCIDENCE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

AFRICA, NORTHERN; ASIA, WESTERN; BEHCET SYNDROME; BLINDNESS; EUROPE; FAR EAST; HUMANS; INCIDENCE; VISION DISORDERS; WORLD HEALTH;

EID: 36749082445     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.124875     Document Type: Editorial

References (18)

1. Behçet H. Uber rez idivierende, aphhose, durch ein virus verursachte Geschwure am Munde, am Auge und an Genitalien. Dermatol Wochenschr 1937;105:1152-57.
2. Feigenbaum A. Description of Behçet's syndrome in the Hippocratic third book of endemic disease. Br J Ophthalmol 1956;40:355-57.
3. Nussenblatt RB, Whilcup SW. Uveitis. Fundamentals and clinical practice, 3rd edn.St. Louis: Mosby, 2004:350-71.
4. Mochizuki M, Akduman L, Nussenblatt RB. Behçet's disease. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunily.St.Louis: Mosby, 1996:063-675.
5. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol 1997;14:67-79.
6. Yates PA, Michelson JB. Behçet's disease. Int Ophthalmol Clin 2006;46:209-33.
7. Okada AA. Behçet's disease: general concepts and recent advances. Curr Opin Ophthalmol 2006;17:551-6.
8. Atmaca LS. Fundus changes associated with Behçet's disease. Graefe's Arch Clin Exp Ophthalmol 1989;227:340-4.
9. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet's disease:an analysis of 880 patients. Am J Ophthalmol 2004;138:373-80.
10. Kural-Seyahi E, Fresco I, Sayahi N, et al. The long-term mortality and morbidity of Behçet's syndrome:a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60-76.
11. Yoshida A, Kawashima H, Motoyama Y, et al. Comparision of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 2004;111:810-5.
12. Kitaichi N, Miyazaki A, Stanford MR, et al. Ocular features of Behçet's disease: An international collaborative study. Br J Ophthalmol 2007;91:1579-82.
13. The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509- 516.
14. Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256-05.
15. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rhematol 2004;31:1362-8.
16. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum 2005;52:2478-84.
17. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-912.
18. Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999;54:213-20.